Welcome To Recro Pharma
Recro Pharma, Inc. is a venture-backed, specialty biopharmaceutical company headquartered in Malvern, Pennsylvania (greater Philadelphia area). Our mission is to develop differentiated, high value, prescription drugs for analgesia, anesthesia, sedation and other specialty markets. Recro Pharma is currently focusing on proprietary drug solutions for chronic pain resulting from cancer, musculosckeletal disorders, and peripheral neuropathy; cancer breakthrough pain; and acute post-operative pain. Our goal is to leverage our drug development expertise along with innovative delivery systems to optimize absorption, improve effectiveness, and reduce side effects to optimize pain relief and improve quality of life for the millions of people suffering from moderate-to-severe pain annually. Multiple delivery systems are being developed, including intrathecal/epidural, transdermal, intranasal, and sublingual platforms.
Recro Pharma is structured to reduce development risks and get products to market quickly:
- Small in size to allow for flexibility and fast decision-making
- Highly experienced in-house development team including clinical, regulatory, quality assurance/control, drug safety, and manufacturing
- Leadership with a track record of successful product development and commercialization
- New Product Marketing/Business Development team to establish collaborative partnerships with other organizations
January 2010:
DEX-TD Phase I Clinical
Study initiated.
December 2009:
William Ashton joins Board
of Directors.
September 2009:
DEX-SL Phase I Clinical Study initiated in the U.S.
